NCT02678572Phase 3Completed

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Study sponsor: Delcath Systems Inc. · DCTH

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-05-18Actual
Enrollment · participants102Actual
Source updated2026-09-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Objective Response Rate (ORR) as determined by Independent Central Review Committee. After: Measure: Objective Response Rate (ORR) as Determined by Independent Central Review Committee..

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview